We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Social Media, Exclusivity Emerge as Top Controversial Issues in FDA Overhaul
Social Media, Exclusivity Emerge as Top Controversial Issues in FDA Overhaul
A proposal to lift restrictions on how drugmakers can promote products on social media and another that would grant up to 15 years of generics-free exclusivity to drugs approved to treat an unmet medical need are emerging as controversial issues in a proposal to overhaul the FDA’s drug approval processes.